ADAP - Adaptimmune Therapeutics plc
11.74 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 12.38 |
| Open | 0.00 |
| Bid | 11.75 x 900 |
| Ask | 12.50 x 1300 |
| Day's Range | 11.73 - 12.22 |
| 52 Week Range | 4.28 - 14.62 |
| Volume | 546,215 |
| Avg. Volume | 504,920 |
| Market Cap | 1.105B |
| Beta | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.74 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.17 |
- CNBC Videos•last month
Cramer's lightning round: Take a pass on Bristol-Myers Sq...
Jim Cramer fires off his take on callers' favorite stocks, including a biopharmaceutical play facing a rival.
- GlobeNewswire•8 days ago
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑ cells ...
- ACCESSWIRE•12 days ago
Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
- GlobeNewswire•15 days ago
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
-Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts-. -Dosing continues with the one billion“ target” cell dose-. PHILADELPHIA, Pa. and OXFORD, U.K., June ...
- GlobeNewswire•15 days ago
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
-No evidence of off-target toxicity at 100 million cells for second wholly owned asset-. -Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study-. PHILADELPHIA, ...
- GlobeNewswire•17 days ago
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells ...
- GlobeNewswire•18 days ago
Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering Underlying Factors of Influence
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK ...
- GlobeNewswire•last month
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K., May 16, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting ...
- CNBC•last month
Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Clorox : "Clorox is caught up in this whole vortex of the 10-year Treasury going above 3 percent yield.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ADAP earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Adaptimmune Therapeutics PLC Earnings Call
- ACCESSWIRE•last month
Wired News – VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine
LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VBIV as the Company's latest news hit the wire. On May 10, 2018, the commercial-stage biopharmaceutical Company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology, reported positive results from the randomized, placebo-controlled Phase-1 study of VBI-1501. Active-Investors.com is currently working on the research report for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), which also belongs to the Healthcare sector as the Company VBI Vaccines.
- Benzinga•last month
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- GlobeNewswire•last month
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
-Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose-. -Updated MRCLS response data will be presented in an oral presentation at ASCO-. -Guidance confirmed, funded through to ...
- GlobeNewswire•2 months ago
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general ...
- GlobeNewswire•2 months ago
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
-Preclinical testing raises no safety concerns for MAGE A4-- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity-. PHILADELPHIA, Pa. and OXFORD, United ...
- GlobeNewswire•2 months ago
Adaptimmune Announces Changes to Board of Directors
PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed ...
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 ...
- TheStreet.com•3 months ago
4 Strong Buy Biotech Stocks Poised to Explode
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
- Investopedia•3 months ago
Adaptimmune Stock: How Long Will Rally Continue?
Adaptimmune shares have rallied following positive initial results from its T-cell receptor platform, but traders will be watching these levels.
- Reuters•3 months ago
GlaxoSmithKline prescribes commercial reboot for pharma division
In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritised plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.
- Investopedia•3 months ago
3 Hot Junior Biotech Plays
These three small-cap biotech stocks are attracting significant buying interest in this mixed March environment.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ADAP earnings conference call or presentation 15-Mar-18 12:00pm GMT
Q4 2017 Adaptimmune Therapeutics PLC Earnings Call
- Motley Fool•3 months ago
Why Noodles & Co., Blue Apron Holdings, and Adaptimmune Therapeutics Jumped Today
Find out why these stocks climbed on a mixed day for Wall Street.
- Motley Fool•3 months ago
Here's What Lifted Adaptimmune Therapeutics plc Today
A handful of responses from cancer patients with solid tumors pleased investors.
